French agency prioritizes innovation, drug safety and early access
This article was originally published in Scrip
The French regulator ANSM has laid out a wide-ranging set of plans in its work program for 2015, including ensuring rapid and wider access to innovation, guaranteeing the safety of products throughout their life cycle, and using regulatory tools to speed up the availability of innovative new drugs.
You may also be interested in...
At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.